Dummy Whitepaper Storefront
The Role of Technology in Reducing Risks Associated with CRBSI
The white paper states that intravenous (IV) therapy is the primary route for therapeutic regimens in acute care setting. Approximately 87% of bloodstream infections are associated with the presence of some type of intravascular device.
The report explains that some needleless connector designs have been associated with an increase in catheter-related bloodstream infections (CRBSI), costly and serious hospital-acquired infections that occur nationally at a rate of nearly one a minute.
In the United States, the estimated rate of CRBSIs ranges from 3% to 7%, these infections have an additional cost of care estimated at $25,000 to $45,000 an episode.
A prospective study of CRBSI in pediatric cancer patients has found the type of device and care setting to be the most significant clinical variables, with repeated manipulation of multilumen catheters a major mechanism for hub contamination.
The paper details the central-line bundle recommendations as hand hygiene, maximal sterile barrier precautions, CHG skin antisepsis, optimal catheter site selection and daily review of line necessity.